House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Cardiology

Dyslipidaemias: 2025 focused update

ESC / EAS · 2025 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The ESC/EAS focused update revises selected recommendations for cardiovascular risk assessment and lipid-lowering treatment. It supplements the prior dyslipidaemia guideline, with new recommendations spanning primary prevention, acute coronary syndromes, statin intolerance and several special populations.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Estimate risk in the appropriate population

  • Use SCORE2 in apparently healthy people younger than 70 without established ASCVD, diabetes, CKD or genetic/rare lipid or blood-pressure disorders. It estimates 10-year fatal and non-fatal cardiovascular risk. [1]
  • Use SCORE2-OP in apparently healthy people aged at least 70 without established ASCVD, diabetes, CKD or genetic/rare lipid or blood-pressure disorders, to estimate 10-year fatal and non-fatal cardiovascular risk. [1]
  • Consider imaging evidence of subclinical coronary atherosclerosis or increased coronary calcium to refine classification in moderate-risk people or those near a treatment decision threshold. Other risk modifiers should also be considered in these groups. [1]
  • Consider lipoprotein(a) above 50 mg/dL (105 nmol/L) a risk-enhancing factor in adults. Higher concentrations are associated with a greater increase in cardiovascular risk. [1]

Apply LDL-C treatment thresholds after non-drug measures

  • In primary prevention, pharmacological LDL-C reduction is recommended despite optimized non-pharmacological measures for very-high-risk people with LDL-C at least 1.8 mmol/L (70 mg/dL), or high-risk people with LDL-C at least 2.6 mmol/L (100 mg/dL). [1]
  • After optimized non-pharmacological measures, treatment should be considered at LDL-C 1.4 to below 1.8 mmol/L in very-high-risk people, or 1.8 to below 2.6 mmol/L in high-risk people. The lower boundary is inclusive in each group. [1]
  • Treatment should also be considered after optimized non-pharmacological measures for moderate-risk people with LDL-C at least 2.6 but below 4.9 mmol/L, and low-risk people with LDL-C at least 3.0 but below 4.9 mmol/L. [1]

Choose additional or alternative LDL-C therapies

  • If statins cannot be taken, use non-statin treatment with proven cardiovascular benefit, alone or in combination. Select treatment according to the additional LDL-C reduction needed. [1]
  • Bempedoic acid is recommended to achieve the LDL-C goal in people unable to take a statin. [1]
  • In high- or very-high-risk patients, consider adding bempedoic acid to the maximally tolerated statin, with or without ezetimibe, to reach the LDL-C goal. [1]
  • Consider evinacumab for homozygous familial hypercholesterolaemia from age 5 when maximum lipid-lowering treatment has not achieved the LDL-C goal. [1]

Intensify treatment during the index ACS admission

  • For patients already taking any lipid-lowering treatment before admission, intensification during the index acute coronary syndrome hospitalization is recommended to lower LDL-C further. [1]
  • For treatment-naïve ACS patients unlikely to reach the LDL-C goal with a statin alone, consider starting a high-intensity statin plus ezetimibe during the index admission. [1]

Use triglyceride therapies in the stated groups

  • Consider icosapent ethyl 2 × 2 g/day with a statin in high- or very-high-risk patients whose fasting triglycerides are 135–499 mg/dL (1.52–5.63 mmol/L), to reduce cardiovascular events. [1]
  • Consider volanesorsen 300 mg/week for familial chylomicronaemia syndrome with severe hypertriglyceridaemia above 750 mg/dL (8.5 mmol/L), to lower triglycerides and pancreatitis risk. [1]

Address HIV, cancer therapy and supplements

  • For primary prevention in people with HIV aged at least 40, statin treatment is recommended regardless of estimated cardiovascular risk or LDL-C. Choose the statin with potential drug interactions in mind. [1]
  • Consider statins in adults at high or very high risk of chemotherapy-related cardiovascular toxicity to reduce anthracycline-associated cardiac dysfunction. [1]
  • Do not recommend supplements or vitamins for ASCVD prevention when documented safety and significant LDL-C-lowering efficacy are absent. [1]

Limitations and use

  • This is a focused update, not a replacement for the base guideline. The reviewed official recommendation slides omit the graphical LDL-C goal charts and intervention-strategy figures, so their complete treatment matrix cannot be reconstructed here. Drug-specific monitoring, contraindications and unquoted prescribing details are not supplied by this extract.
  • This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Dyslipidaemias: 2025 focused update — focused recommendation source

    Selected recommendation material consulted

Focused guideline update

Publication details

Issuing organisation
ESC / EAS
First published
29 August 2025
Resource type
Focused guideline update · House clinical summary
Source setting
Europe

Read alongside the base guideline: dyslipidaemia management esc. This focused update changes selected recommendations.

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Estimate risk in the appropriate population
  • Apply LDL-C treatment thresholds after non-drug measures
  • Choose additional or alternative LDL-C therapies
  • Intensify treatment during the index ACS admission
  • Use triglyceride therapies in the stated groups
  • Address HIV, cancer therapy and supplements
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House